Identification of differentially expressed serum proteins in gastric adenocarcinoma

Journal of Proteomics

Volumn 127, Issue , 2015, Pages 80-88

  Subbannayya, Yashwanth ^a,b,c   Mir, Sartaj Ahmad ^a,f   Renuse, Santosh ^a,d,i   Manda, Srikanth S ^a,e   Pinto, Sneha M ^a,f   Puttamallesh, Vinuth N ^a   Solanki, Hitendra Singh ^a   Manju, H C ^a   Syed, Nazia ^a,e   Sharma, Rakesh ^g   Christopher, Rita ^g   Vijayakumar, M ^c   Veerendra Kumar, K V ^c   Keshava Prasad, T S ^a   Ramaswamy, Girija ^c   Kumar, Rekha V ^c   Chatterjee, Aditi ^a   Pandey, Akhilesh ^h   Gowda, Harsha ^a  

^a INSTITUTE OF BIOINFORMATICS   (India)

^b RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES   (India)

^c KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^d AMRITA UNIVERSITY   (India)

^e PONDICHERRY UNIVERSITY   (India)

^f MANIPAL UNIVERSITY   (India)

^g NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Thermo Fisher Scientific   (United States)

Author keywords

Body fluid; In vitro labeling; LC MS MS analysis; Mass spectrometry; Serum proteome

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; MANNOSE BINDING PROTEIN; MANNOSE BINDING PROTEIN C; OROSOMUCOID; OROSOMUCOID 1; PLASMA PROTEIN; SERUM AMYLOID A; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; FEMALE; GENE EXPRESSION REGULATION; MALE; STOMACH TUMOR;

ADENOCARCINOMA; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; STOMACH NEOPLASMS;

EID: 84943197533     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.04.021     Document Type: Article

References (63)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Roth A.D. Curative treatment of gastric cancer: towards a multidisciplinary approach?. Crit Rev Oncol Hematol 2003, 46:59-100.
3. Krejs G.J. Gastric cancer: epidemiology and risk factors. Dig Dis 2010, 28:600-603.
4. Kulasingam V., Diamandis E.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008, 5:588-599.
5. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
6. Zolotarjova N., Martosella J., Nicol G., Bailey J., Boyes B.E., Barrett W.C. Differences among techniques for high-abundant protein depletion. Proteomics 2005, 5:3304-3313.
7. Sakamoto K., Haga Y., Yoshimura R., Egami H., Yokoyama Y., Akagi M. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987, 28:323-329.
8. Pectasides D., Mylonakis A., Kostopoulou M., Papadopoulou M., Triantafillis D., Varthalitis J., et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997, 20:348-353.
9. Haglund C., Kuusela P., Roberts P., Jalanko H. Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest 1991, 51:265-270.
10. Ychou M., Duffour J., Kramar A., Gourgou S., Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 2000, 16:105-110.
11. Loei H., Tan H.T., Lim T.K., Lim K.H., So J.B., Yeoh K.G., et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res 2012, 11:1759-1772.
12. Marimuthu A., Subbannayya Y., Sahasrabuddhe N.A., Balakrishnan L., Syed N., Sekhar N.R., et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin Appl 2013, 7:355-366.
13. Yang Y., Lim S.K., Choong L.Y., Lee H., Chen Y., Chong P.K., et al. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 2010, 9:4767-4778.
14. Chong P.K., Lee H., Loh M.C., Choong L.Y., Lin Q., So J.B., et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010, 10:3210-3221.
15. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85.
16. Subbannayya Y., Syed N., Barbhuiya M.A., Raja R., Marimuthu A., Sahasrabuddhe N., et al. Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma. Cancer Biol Ther 2015, 16:336-345.
17. Keshava Prasad T.S., Goel R., Kandasamy K., Keerthikumar S., Kumar S., Mathivanan S., et al. Human Protein Reference Database-2009 update. Nucleic Acids Res 2009, 37:D767-D772.
18. Keshava Prasad T.S., Kandasamy K., Pandey A. Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol 2009, 577:67-79.
19. Lange V., Picotti P., Domon B., Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222.
20. Balakrishnan L., Bhattacharjee M., Ahmad S., Nirujogi R.S., Renuse S., Subbannayya Y., et al. Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients. Clin Proteomics 2014, 11:1.
21. MacLean B., Tomazela D.M., Shulman N., Chambers M., Finney G.L., Frewen B., et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26:966-968.
22. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501-523.
23. Conti P., Bartle L., Barbacane R.C., Reale M., Placido F.C., Sipe J. Synergistic activation of serum amyloid A (SAA) by IL-6 and IL-1 in combination on human Hep 3B hepatoma cell line. Role of PGE2 and IL-1 receptor antagonist. Immunol Invest 1995, 24:523-535.
24. Rashid S.A., O'Quigley J., Axon A.T., Cooper E.H. Plasma protein profiles and prognosis in gastric cancer. Br J Cancer 1982, 45:390-394.
25. Sasazuki S., Inoue M., Sawada N., Iwasaki M., Shimazu T., Yamaji T., et al. Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. Carcinogenesis 2010, 31:712-718.
26. Chan D.C., Chen C.J., Chu H.C., Chang W.K., Yu J.C., Chen Y.J., et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007, 14:84-93.
27. Kwon H.C., Kim S.H., Oh S.Y., Lee S., Lee J.H., Jang J.S., et al. Clinicopathologic significance of expression of nuclear factor-kappaB RelA and its target gene products in gastric cancer patients. World J Gastroenterol 2012, 18:4744-4750.
28. Wood S.L., Rogers M., Cairns D.A., Paul A., Thompson D., Vasudev N.S., et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 2010, 103:101-111.
29. Wang J.Y., Zheng Y.Z., Yang J., Lin Y.H., Dai S.Q., Zhang G., et al. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer 2012, 12:365.
30. Jung Y.D., Ahmad S.A., Liu W., Reinmuth N., Parikh A., Stoeltzing O., et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 2002, 12:105-112.
31. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
32. Schaaij-Visser T.B., de Wit M., Lam S.W., Jimenez C.R. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 1834, 2013:2242-2258.
33. Uen Y.H., Lin K.Y., Sun D.P., Liao C.C., Hsieh M.S., Huang Y.K., et al. Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. J Proteomics 2013, 83:197-213.
34. Liu W., Liu B., Cai Q., Li J., Chen X., Zhu Z. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta 2012, 413:1098-1106.
35. Ren H., Du N., Liu G., Hu H.T., Tian W., Deng Z.P., et al. Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol 2006, 12:2789-2792.
36. Piver M.S., Moyer M., Diakun K., Lele S.B., Chu T.M. Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol Oncol 1988, 29:305-308.
37. Matsuura H., Nakazawa S. Prognostic significance of serum alpha 1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication. J Neurol Neurosurg Psychiatry 1985, 48:835-837.
38. Hsu P.I., Chen C.H., Hsiao M., Wu D.C., Lin C.Y., Lai K.H., et al. Diagnosis of gastric malignancy using gastric juice alpha1-antitrypsin. Cancer Epidemiol Biomarkers Prev 2010, 19:405-411.
39. Kwon C.H., Park H.J., Lee J.R., Kim H.K., Jeon T.Y., Jo H.J., et al. Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer. Br J Cancer 2014, 111:1993-2002.
40. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., Wang T.T., et al. ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 2010, 9:3671-3679.
41. Paris S., Sesboue R., Delpech B., Chauzy C., Thiberville L., Martin J.P., et al. Inhibition of tumor growth and metastatic spreading by overexpression of inter-alpha-trypsin inhibitor family chains. Int J Cancer 2002, 97:615-620.
42. Wang X., Abraham S., McKenzie J.A., Jeffs N., Swire M., Tripathi V.B., et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 2013, 499:306-311.
43. Narayanasamy A., Ahn J.M., Sung H.J., Kong D.H., Ha K.S., Lee S.Y., et al. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics 2011, 74:2948-2958.
44. Lin Y., Kikuchi S., Obata Y., Yagyu K. Serum copper/zinc superoxide dismutase (Cu/Zn SOD) and gastric cancer risk: a case-control study. Jpn J Cancer Res 2002, 93:1071-1075.
45. Yasuda M., Takesue F., Inutsuka S., Honda M., Nozoe T., Korenaga D. Prognostic significance of serum superoxide dismutase activity in patients with gastric cancer. Gastric Cancer 2002, 5:148-153.
46. Syversen U., Ramstad H., Gamme K., Qvigstad G., Falkmer S., Waldum H.L. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004, 39:969-973.
47. Kelley K.M., Oh Y., Gargosky S.E., Gucev Z., Matsumoto T., Hwa V., et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996, 28:619-637.
48. Png K.J., Halberg N., Yoshida M., Tavazoie S.F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012, 481:190-194.
49. Hu Q., Huang L., Kuang X., Zhang H., Ling G., Chen X., et al. Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?. Clin Exp Metastasis 2014, 31:535-541.
50. Sunderic M., Dukanovic B., Malenkovic V., Nedic O. Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. Exp Mol Pathol 2014, 96:48-53.
51. Guo C., Lu H., Gao W., Wang L., Lu K., Wu S., et al. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One 2013, 8:e74973.
52. Shi L.H., Zhu X.Q., Zhao G.H., Xia Y.B., Zhang Y.S. Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation. World J Gastroenterol 2006, 12:6285-6289.
53. Pineiro M., Alava M.A., Gonzalez-Ramon N., Osada J., Lasierra P., Larrad L., et al. ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 1999, 263:224-229.
54. van den Broek I., Sparidans R.W., van Winden A.W., Gast M.C., van Dulken E.J., Schellens J.H., et al. The absolute quantification of eight inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics Clin Appl 2010, 4:931-939.
55. Jayapalan J.J., Ng K.L., Shuib A.S., Razack A.H., Hashim O.H. Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter-alpha-trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment. Electrophoresis 2013, 34:1663-1669.
56. Abdullah-Soheimi S.S., Lim B.K., Hashim O.H., Shuib A.S. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 2010, 8:58.
57. Ghazi M., Isadyar M., Gachkar L., Mahmoudi S., Goudarzi H., Eslami G., et al. Serum levels of mannose-binding lectin and the risk of infection in pediatric oncology patients with chemotherapy. J Pediatr Hematol Oncol 2012, 34:128-130.
58. Zanetti K.A., Haznadar M., Welsh J.A., Robles A.I., Ryan B.M., McClary A.C., et al. 3'-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res 2012, 72:1467-1477.
59. Zhou J.Y., Shi R., Yu H.L., Zheng W.L., Ma W.L. Association between SHBG Asp327Asn (rs6259) polymorphism and breast cancer risk: a meta-analysis of 10,454 cases and 13,111 controls. Mol Biol Rep 2012, 39:8307-8314.
60. Nakhla A.M., Rosner W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. Endocrinology 1996, 137:4126-4129.
61. Kataoka N., Cai Q., Xu W.H., Xiang Y.B., Cai H., Zheng W., et al. Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene. Cancer 2007, 109:1296-1302.
62. Su H., Hu N., Yang H.H., Wang C., Takikita M., Wang Q.H., et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Clin Cancer Res 2011, 17:2955-2966.
63. Liu C., Pan C., Shen J., Wang H., Yong L. Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. Oncol Lett 2012, 3:1259-1262.